Strategic Overview
Track A: QuantumGenic™ Core Technology Licensing
A platform to license the four proprietary core ingredients to pharmaceutical, nootropic, and nutraceutical companies.
Track A: QuantumGenic™ (QG) Licensing of Core Ingredients (IP-Based Platform)
Medical Vision
Revolutionize compound delivery in modern medicine
Four Proprietary Core Compounds
Unique plant-based delivery platform
Market Opportunity
Pharmaceutical licensing worth €10M-€50M per deal
Competitive Edge
100% plant-based, biocompatible, modular
Core Vision and Mission
To revolutionize compound delivery in modern medicine and supplements by offering a plant-based, IP-protected core system that enhances absorption, cellular targeting, and neuro-adaptive performance.
The Four Proprietary Core Compounds
- NanoCarrier Matrix – Enables targeted compound delivery and sustained nutrient absorption.
- LiptoCore Biotic Complex – Promotes adaptive cellular regeneration, nutrient priming, and synchronized compound integration.
- Lipid Transduction Agent – Facilitates emulsification, barrier permeability, and compound transport.
- Microbiotic Release Core – Provides structural consistency and time-release capabilities for multi-compound blends.
(Full descriptions remain confidential. Technical disclosures available under NDA.)
Technology Platform Benefits
Intelligent Delivery Platform
This unique combination of plant-based compounds forms a synergistic, intelligent delivery platform that enhances absorption, optimizes targeted release, and enables integration into a wide range of pharmaceutical and nutraceutical formulations.
Market Opportunity
Pharmaceutical Licensing Benchmarks
Based on industry analyses, pharmaceutical licensing deals commonly include:
- Up-front payments: €10M–€50M per compound for early-stage assets
- Total deal value: €100M–€1B+ when including clinical milestones and royalties
- Royalty rates: Typically 5–10% of net sales
Industry Precedents
Examples:
- Novartis–PTC Therapeutics: €1B up front, €2.9B total
- AstraZeneca–CSPC: €100M up front, €2B total
- Merck–Hengrui: €200M up front, €2B total
Competitive Edge
Key Features
- 100% plant-based, non-synthetic alternative to synthetic bioenhancers or transdermal agents
- Biocompatibility for sensitive and regulated applications (e.g., cognitive disorders, oncology support)
- Modular and combinable with a wide range of active molecules
Regulatory Strategy
WHO-Aligned Compliance Rationale
Operating via EU/UK labs enables harmonized dossier preparation for regulatory approvals (Novel Food or Medical Device Class), and easier integration into multinational clinical pipelines.
Target Partners
Top 20 global pharma and supplement companies (e.g., Nestlé Health Science, GSK, Bayer, Pfizer, Unilever, Abbott, Johnson & Johnson)
- Licensing similar technologies fetch between €10M–€50M per company for exclusive or semi-exclusive usage rights
Licensing Potential
Estimated licensing potential:
- Conservative: 5 companies @ €10M = €50M
- Mid-case: 10 companies @ €25M = €250M
- Aggressive: 20 companies @ €50M = €1B+
These figures support our licensing projections, where even a conservative rollout—5 partners at €10M each—already yields €50M, while mid-tier or exclusive partnerships could scale the return into the hundreds of millions.
Track B: Super Soldier Serum™ - (SSS)
A full-suite wellness platform combining five plant-based superfood formulas with four proprietary core actives.
Track B: Super Soldier Serum™ (SSS) Wellness Platform
Medical Vision
To optimize human brain and body performance through a clinically-backed blend of targeted superfoods and smart delivery systems that activate regenerative pathways and enhance physical and cognitive resilience.
Product Offering
Five Formulas (2000mg Sublingual Pearls):
- Brain Performance & Recovery
- Hormonal Balance (Female Health)
- Immune + Energy + Prevention
- Mental Health & Emotional Resilience
- Sleep & Cellular Regeneration
Each includes the four core ingredients, plus a curated blend of high-potency botanicals.
Market Opportunity
Consumer Wellness Sector (Track A – SSS): Estimated at €2.8 trillion across the U.S. and EU markets.
B2B Licensing Sector (Track B – Proprietary Compounds): Targets global pharmaceutical, nutraceutical, and nootropic markets—valued in the hundreds of billions, with individual licensing deals ranging between €10M–€50M per company.
Projected price: €45–€50/unit Target penetration: 0.05% (Year 1) scaling to 0.2% (Year 5)
Projected revenues:
- Year 1: €500K–€750K
- Year 2: €2.5M–€3.5M
- Year 5: €20M–€100M
Competitive Edge
- Combines full-spectrum superfoods with advanced delivery tech
- Addresses five major health domains with synergy, not isolation
- Supported by pilot clinical trial roadmap (Q4 2025)
Meet With Our Founder: Dr. Gemi Bertran
Academic Excellence
PhD in Nutritional Science with specialization in molecular biology.
MBA focused on biotech innovation and commercialization strategies.
Published researcher in cellular metabolism and nutrigenomics.
Visionary Leadership
Founder of Nourish the Brain Institute, pioneering nutritional therapeutics.
Government Recognition
Secured GSA Contract #47QREA23D002D and WOSB certification #200521.
QuantumGenic™ Vision
Leading the dual-track strategy combining IP licensing with advanced formulations.